COVID-19

Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules

Carlsbad, CA, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic…

2 years ago

Join GCEA for 5th International Clinical Engineering & HTM Congress in Visakhapatnam, India

Arlington, Virginia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Are you interested in promoting international cooperation in clinical engineering and healthcare…

2 years ago

Moderna to Participate at Morgan Stanley 21st Annual Global Healthcare Conference

CAMBRIDGE, MA / ACCESSWIRE / September 6, 2023 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in a fireside chat…

2 years ago

New Analysis Shows Reduction in Annual Patient Costs and Medical Claims with Medisafe

According to the analysis, MS and epilepsy patients experienced reduced annual healthcare costs of $6,280 and $4,600, respectively, on average…

2 years ago

Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs

Experienced Biopharma/Pharmaceutical Executive to Lead Implementation of cGMP-quality LineaDNA™ Capability for IVT mRNA ProductionPreviously Led Manufacturing Operations Scale-up for the…

2 years ago

Predictmedix AI’s 2023 Breakthroughs: Pioneering Healthcare Innovation and Global Expansion

TORONTO, ON / ACCESSWIRE / September 6, 2023 / Predictmedix AI Inc. (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP) (the "Company" or "Predictmedix") today provided an…

2 years ago

Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against BA.2.86

CDC notes that the BA.2.86 (Pirola) variant may be more likely to break through existing immunity from previous vaccination or…

2 years ago

Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease

– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND…

2 years ago

Awakn Life Sciences Submits Clinical Trial Application for Phase III Trial of AWKN-P001

AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use DisorderToronto,…

2 years ago